Your provider will review your experience with the current dose, specifically inquiring about gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation, abdominal pain), changes in appetite, signs of dehydration, and any other adverse effects
These have solid appreciation potential plus the size and scale to manage through economic downturns
Discussion The GLP-1-based therapies usually utilize two strategies: 1) inhibition of dipeptidyl peptidase 4 (DPP-4) enzyme with specific inhibitors, such as sitagliptin / vildgliptin, in order to raises plasma levels of endogenous GLP-1 and GIP and 2) utilizing DPP-4 resistant GLP-1 receptor agonists, such as liraglutide / exenatide 44
Wegovy, on the other hand, is a GLP-1 receptor agonist that mimics the natural hormone GLP-1, which plays a key role in appetite control
They also had a 4 percent higher risk of cardiovascular issues than those continually on a sulfonylurea